Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Forest Labs,Replidyne terminate US faropenem medoxomil deal

Executive Summary

Forest Laboratories has licensed rights to develop and market Replidyne's orally bioavailable broad-spectrum antibiotic Orapem (faropenem medoxomil) in the US.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • Includes Contract
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register